Literature DB >> 33515195

Characterizing the Variation of Alcohol Cessation Pharmacotherapy in Primary Care.

Eden Bernstein1, Ning Guo2, Toyomi Goto3, Michael B Rothberg4,5.   

Abstract

BACKGROUND: Alcohol use disorder (AUD) imposes a high mortality and economic burden. Effective treatment is available, though underutilized.
OBJECTIVE: Describe trends in AUD pharmacotherapy, variation in prescribing, and associated patient factors.
DESIGN: Retrospective cohort using electronic health records from 2010 to 2019. PARTICIPANTS: Primary care patients from 39 clinics in Ohio and Florida with diagnostic codes for alcohol dependence or abuse plus social history indicating alcohol use. PCPs in family or internal medicine with at least 20 AUD patients. MAIN MEASURES: Pharmacotherapy for AUD (naltrexone, acamprosate, and disulfiram), abstinence from alcohol, patient demographics, and comorbidities. Generalized linear mixed models were used to identify patient factors associated with prescriptions and the association of pharmacotherapy with abstinence. KEY
RESULTS: We identified 13,250 patients; average age was 54 years, 66.9% were male, 75.0% were White, and median household income was $51,776 per year. Over 10 years, the prescription rate rose from 4.4 to 5.6%. Patients who were Black (aOR 0.74; 95% CI 0.58, 0.94) and insured by Medicare versus commercial insurance (aOR 0.61; 95% CI 0.48, 0.78) were less likely to be treated. Higher median household income ($10,000 increment, aOR 1.06; 95% CI 1.03, 1.10) and Medicaid versus commercial insurance (aOR 1.52; 95% CI 1.24, 1.87) were associated with treatment. Receiving pharmacotherapy was associated with subsequent documented abstinence from alcohol (aOR 1.60; 95% CI 1.33, 1.92). We identified 236 PCPs. The average prescription rate was 3.6% (range 0 to 24%). The top decile prescribed to 14.6% of their patients. The bottom 4 deciles had no prescriptions. Family physicians had higher rates of pharmacotherapy than internists (OR 1.50; 95% CI 1.21, 1.85).
CONCLUSIONS: Medications for AUD are infrequently prescribed, but there is considerable variation among PCPs. Increasing the use of pharmacotherapy by non-prescribers may increase abstinence from alcohol.
© 2021. Society of General Internal Medicine.

Entities:  

Mesh:

Year:  2021        PMID: 33515195      PMCID: PMC8298666          DOI: 10.1007/s11606-020-06454-1

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   6.473


  38 in total

1.  Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics.

Authors:  Emily C Williams; Carol E Achtmeyer; Jessica P Young; Douglas Berger; Geoffrey Curran; Katharine A Bradley; Julie Richards; Michael B Siegel; Evette J Ludman; Gwen T Lapham; Mark Forehand; Alex H S Harris
Journal:  J Gen Intern Med       Date:  2017-10-30       Impact factor: 5.128

Review 2.  Management of opioid use disorder in the USA: present status and future directions.

Authors:  Carlos Blanco; Nora D Volkow
Journal:  Lancet       Date:  2019-03-14       Impact factor: 79.321

3.  Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Emily Cohen; Richard Feinn; Albert Arias; Henry R Kranzler
Journal:  Drug Alcohol Depend       Date:  2006-08-17       Impact factor: 4.492

4.  A randomized clinical trial of alcohol care management delivered in Department of Veterans Affairs primary care clinics versus specialty addiction treatment.

Authors:  David W Oslin; Kevin G Lynch; Stephen A Maisto; Larry J Lantinga; James R McKay; Kyle Possemato; Erin Ingram; Michael Wierzbicki
Journal:  J Gen Intern Med       Date:  2013-09-20       Impact factor: 5.128

5.  Correlates of alcohol use disorder pharmacotherapy receipt in medically insured patients.

Authors:  Alexander Rittenberg; Anika L Hines; Anika A H Alvanzo; Geetanjali Chander
Journal:  Drug Alcohol Depend       Date:  2020-07-15       Impact factor: 4.492

6.  A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition.

Authors:  Molly Magill; Lara Ray; Brian Kiluk; Ariel Hoadley; Michael Bernstein; J Scott Tonigan; Kathleen Carroll
Journal:  J Consult Clin Psychol       Date:  2019-10-10

7.  Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.

Authors:  Tami L Mark; Cheryl A Kassed; Rita Vandivort-Warren; Katharine R Levit; Henry R Kranzler
Journal:  Drug Alcohol Depend       Date:  2008-09-25       Impact factor: 4.492

8.  Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials.

Authors:  Molly Magill; Lara A Ray
Journal:  J Stud Alcohol Drugs       Date:  2009-07       Impact factor: 2.582

9.  Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels.

Authors:  Katie Witkiewitz; Kevin A Hallgren; Henry R Kranzler; Karl F Mann; Deborah S Hasin; Daniel E Falk; Raye Z Litten; Stephanie S O'Malley; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2016-12-26       Impact factor: 3.455

10.  Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis.

Authors:  Lara A Ray; Lindsay R Meredith; Brian D Kiluk; Justin Walthers; Kathleen M Carroll; Molly Magill
Journal:  JAMA Netw Open       Date:  2020-06-01
View more
  1 in total

1.  Treatment for alcohol use disorder among persons with and without HIV in a clinical care setting in the United States.

Authors:  Thibaut Davy-Mendez; Varada Sarovar; Tory Levine-Hall; Alexandra N Lea; Stacy A Sterling; Felicia W Chi; Vanessa A Palzes; Kendall J Bryant; Constance M Weisner; Michael J Silverberg; Derek D Satre
Journal:  Drug Alcohol Depend       Date:  2021-09-28       Impact factor: 4.492

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.